Generate Biomedicines, Inc. Common Stock (GENB) is a publicly traded the market company. As of May 20, 2026, GENB trades at $13.13 with a market cap of $1.67B and a P/E ratio of -12.06. GENB moved +5.07% today. Year to date, GENB is +0.00%; over the trailing twelve months it is flat. Its 52-week range spans $11.00 to $16.75. Analyst consensus is strong buy with an average price target of $25.40. Rallies surfaces GENB's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Generate Biomedicines, Inc. Common Stock (GENB) research on Rallies includes live charts, financials, analyst ratings, hedge fund holdings, politician trades, insider activity, news, AI research, and community context. GENB moved +5.07% today. Analyst consensus is strong buy.
| Metric | Value |
|---|---|
| Price | $13.13 |
| Market Cap | $1.67B |
| P/E Ratio | -12.06 |
| EPS | $-1.07 |
| Dividend Yield | 0.00% |
| 52-Week High | $16.75 |
| 52-Week Low | $11.00 |
| Volume | 827.46K |
| Avg Volume | 0 |
| Revenue (TTM) | $7.22M |
| Net Income | $-61.71M |
| Gross Margin | 0.00% |
6 analysts cover GENB: 0 strong buy, 6 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $25.40.